MyFinsight
Home
Blog
About
Contact
Download
Download image
Net decrease in cash
and restricted cash
-$9,283K
Change in deferred r&d
services and r&d funding...
$1,332K
Stock-based compensation
$897K
Prepaid expenses and
other assets
-$433K
Deferred revenue
$249K
Accounts payable
$121K
Non-cash r&d expense
related to torii warrant...
$106K
Inventory
-$103K
Amortization of finance lease
right-of-use asset
$100K
Amortization of operating
lease right-of-use...
$77K
Collaboration receivable,
billed and unbilled
-$48K
Depreciation expense
$17K
Loss on termination
of financing lease
-$10K
Net cash used in
operating activities
-$9,163K
Net cash used in
financing activities
-$120K
Canceled cashflow
$3,493K
Net loss
-$9,682K
Repayment of finance lease
$111K
Payment of equity
issuance costs
$9K
Accounts receivable
$2,464K
Accrued expenses and
other current...
-$586K
Back
Back
Cash Flow
Verrica Pharmaceuticals Inc. (VRCA)
Verrica Pharmaceuticals Inc. (VRCA)
source: myfinsight.com